{
    "URL": "https://doi.org/10.1371/journal.pntd.0011124",
    "Published": "March 8, 2023",
    "Subject_Areas": [
        "Dengue virus",
        "Dengue fever",
        "Vaccination and immunization",
        "Viral vaccines",
        "Attenuated vaccines",
        "Vaccines",
        "Antibodies",
        "Vaccine development"
    ],
    "Authors": {
        "Vianney Tricou": [
            "Takeda Pharmaceuticals International AG, Zurich, Switzerland"
        ],
        "Brandon Essink": [
            "Meridian Clinical Research, Omaha, Nebraska, United States of America"
        ],
        "John E. Ervin": [
            "Center for Pharmaceutical Research Inc, Kansas City, Missouri, United States of America"
        ],
        "Mark Turner": [
            "Advanced Clinical Research, Boise, Idaho, United States of America"
        ],
        "Ian Escudero": [
            "Takeda Vaccines Pte. Ltd., Singapore"
        ],
        "Martina Rauscher": [
            "Takeda Pharmaceuticals International AG, Zurich, Switzerland"
        ],
        "Manja Brose": [
            "Takeda Pharmaceuticals International AG, Zurich, Switzerland"
        ],
        "Inge Lefevre": [
            "Takeda Pharmaceuticals International AG, Zurich, Switzerland"
        ],
        "Astrid Borkowski": [
            "Takeda Pharmaceuticals International AG, Zurich, Switzerland"
        ],
        "Derek Wallace": [
            "Takeda Vaccines Inc., Boston, Massachusetts, United States of America"
        ]
    }
}